Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)- N-(tetrahydro-2 H-pyran-4-yl)piperidin-4 Amine
2. Btrx-335140
3. Cym-53093
1. Btrx-335140
2. 2244614-14-8
3. Cym-53093
4. Xk5ilz28ki
5. 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-n-(tetrahydro-2h-pyran-4-yl)piperidin-4 Amine
6. 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-n-(tetrahydro-2h-pyran-4-yl)piperidin-4-amine
7. 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-n-(oxan-4-yl)piperidin-4-amine
8. 4-piperidinamine, 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-2-quinolinyl)-n-(tetrahydro-2h-pyran-4-yl)-
9. Unii-xk5ilz28ki
10. Nmra-140
11. Chembl4592045
12. Schembl20670520
13. Gtpl10452
14. Btrx335140
15. Dtxsid401104655
16. Bcp32121
17. Cym53093
18. Ex-a5654
19. Bdbm50531908
20. Compound 58 [pmid: 30707578]
21. Hy-124754
22. Cs-0087593
23. Btrx 335140; Btrx335140; Cym-53093; Cym 53093; Cym53093
| Molecular Weight | 453.6 g/mol |
|---|---|
| Molecular Formula | C25H32FN5O2 |
| XLogP3 | 4.7 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | 453.25400344 g/mol |
| Monoisotopic Mass | 453.25400344 g/mol |
| Topological Polar Surface Area | 76.3 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 630 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Navacaprant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Navacaprant, including repackagers and relabelers. The FDA regulates Navacaprant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Navacaprant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Navacaprant supplier is an individual or a company that provides Navacaprant active pharmaceutical ingredient (API) or Navacaprant finished formulations upon request. The Navacaprant suppliers may include Navacaprant API manufacturers, exporters, distributors and traders.
Navacaprant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Navacaprant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Navacaprant GMP manufacturer or Navacaprant GMP API supplier for your needs.
A Navacaprant CoA (Certificate of Analysis) is a formal document that attests to Navacaprant's compliance with Navacaprant specifications and serves as a tool for batch-level quality control.
Navacaprant CoA mostly includes findings from lab analyses of a specific batch. For each Navacaprant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Navacaprant may be tested according to a variety of international standards, such as European Pharmacopoeia (Navacaprant EP), Navacaprant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Navacaprant USP).
LOOKING FOR A SUPPLIER?
